Currently Viewing:
Evidence-Based Oncology October 2016
Making Oncologists Good Neighbors
Michael Kolodziej, MD
Filling the Donut Hole in Oncology Care With Collaboration and Navigation
Surabhi Dangi-Garimella, PhD
Multi-Level Approach to Addressing Iatrogenic Infertility
Aditi Narayan, MSW; Loyce Pace, MPH; Rebekkah Schear, MIA
Enhancing Healthcare Delivery Research at the National Cancer Institute
Ann M. Geiger, MPH, PhD; Ashley W. Smith, PhD, MPH; Sarah C. Kobrin, PhD, MPH; and Stephen H. Taplin, MD
Learning About Oncologist—Patient Communications by Speaking Directly With Each
Daniel Weber, MPM, and Shelley Fuld Nasso, MPP
Minding the Gaps and Filling the Chasms in Oncology
Joseph Alvarnas, MD
A Holistic Approach to Cancer Care: Focus on Collaboration
Surabhi Dangi-Garimella, PhD
ASCO President Dr Daniel F. Hayes Applauds Recommendations for Cancer Moonshot
Surabhi Dangi-Garimella, PhD
Obesity: A Growing Burden for Cancer Survivors
Priyam Vora
NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death
Surabhi Dangi-Garimella, PhD
Intervention Improved Oncologist-Patient Communication, Not QOL or Hospice Use
Surabhi Dangi-Garimella, PhD
Currently Reading
A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma
Surabhi Dangi-Garimella, PhD

A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma

Surabhi Dangi-Garimella, PhD
A new study by researchers at the Perelman School of Medicine at the University of Pennsylvania has identified a biomarker that can predict response to treatment with pembrolizumab in stage IV patients with melanoma.
Predictive biomarkers—those that can ascertain the success of a treatment—can be very useful in deciding early on if a patient should continue on a treatment plan. Now, a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania has identified such a biomarker in stage IV patients with melanoma being treated with the immunotherapy pembrolizumab (Keytruda).

In their study presented at the CRICIMT- EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, the authors found that the ratio of a subset of immune cells in the blood to the tumor burden correlated with clinical response. “We set out to investigate whether we could monitor and predict a patient’s response to pembrolizumab by tracking the effect of pembrolizumab on immune cells in blood samples from the patients,” said lead author Alexander Huang, MD, clinical fellow in the Division of Hematology/ Oncology and Institute for Immunology at Perelman.

The researchers monitored 29 patients with advanced stage IV melanoma by analyzing immune cells in their blood that was collected before and at 3, 6, 9, and 12 weeks after initiating treatment with pembrolizumab. The authors were primarily interested in following the proliferation of exhausted phenotype CD8+ T cells, which have high levels of programmed death ligand-1 (PD-L1) on their cell surface. These cells are so named because they are no longer capable of inhibiting tumor cells. Pembrolizumab can reinvigorate exhausted phenotype CD8+ T cells, which can be measured by their proliferative capacity.

The authors identified increased proliferation of exhausted phenotype CD8+ T cells in 78% of patients, post treatment. When they calculated the ratio of exhausted phenotype CD8+ T cell reinvigoration to pretreatment tumor burden, a correlation with clinical response was noted. Using this calculation, a clinical response was observed in 38% patients. In one cohort, half the patients with a clinical response exceeding 1.94 were alive at 11-months post treatment with pembrolizumab. In another cohort, 75% of patients with a ratio greater than 1.94 were alive a 2-years post treatment. “We were excited to find that patients with a balance in favor of the immune response compared to tumor burden were more likely to have clinical benefit,” Huang said, adding that their findings need validation in a larger study.
Reference

Ratio of certain immune cells to tumor burden correlated with outcome for pembrolizumab-treated patients with melanoma [press release]. New York, NY: American Association for Cancer Research; September 26, 2016. http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=939#.V-qy9_krLIX. Accessed September 26, 2016.
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!